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1. Introduction 
The term brachytherapy derives from the Greek “brachys”, which means “short” or “close”. 
It is the branch of radiotherapy in which the radioactive source is located near the 
therapeutic target. The reported first use of endobronchial brachytherapy (EBBT) done by 
Yankauer in 19921,. He inserted Radon seeds directly into lung tumors though a rigid 
bronchoscope.  
Recent technological development of brachytherapy equipment with small and high dose 
rate sources, clinical application of EBBT became safe, fast, remote, precise, and less invasive 
(Fig 1), expanding its indication and feasibility in symptomatic palliation and curative 
treatment.  
One of the major role of EBBT is palliation of symptoms caused by endobronchial cancer 
ingrowth. Boost EBBT to endobronchial gross tumors combined with external beam 
radiotherapy (EBRT) provides not only palliative but curative possibilities2. In small 
endobronchial tumors EBBT is used as definitive curative treatment3.EBBT is also used for 
non-oncologic pathologies4,5. The majority of non-small cell lung cancer (NSCLC)found at 
loco-regionally advanced stage and frequently associated with bronchial obstruction 
Various endoscopic techniques available today are including cryotherapy, stent, laser, 
photodynamic, and EBBT6,7. Among these EBBT in the only one that provides biologically 
tumoricidal effect keeping the normal tissue structure as is. 
The National Institute for Cancer in Santiago, Chile (Instituto Nacional del Cáncer de 
Santiago de Chile) has had EBBT HDR since October 2004, and began treating patients in 
March 2006, along with the Bronchoscopy department in Chest National Institute. The 
purpose of this work is to analyze of the result obtained in our center in the palliation of 
symptoms related to the tumor obstruction of the airway, and literature review. 
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Fig. 1. Varisourse Brachytherapy equipment (patient with a catheter in airway during 
treatment) 
2. Patients, materials and methods 
From March 2006 to November 2009, 27 patients were treated with 82 HDR-EBBT 
procedures as palliative treatment for advanced cancer.  
The indication criteria for included: Being able to tolerate decubitus supine position that 
allows fiberrbronchoscopy examination(FBC), there were clear evidence of tumors with 
intraluminal component (with or without extrabronchial component), life expectancy of 
over 3 months, no immediately life-threatening airway obstruction , and healthy coagulating 
condition. All patients were clinically assessed and the symptoms were evaluated according 
to Speiser and Spratling8, recommended by American Brachytherapy Society (ABS), (table 
1), prior to and one week after the end of the treatment.  
Premedication including included sedatives, and local endobronchial anesthesia which were 
commonly used in usual FBC.  
We used two equipment: 
a. Video bronchoscope Fujinon, model EB-270S working channel of 2.0 mm, flexible tube 
of 4.9 mm in diameter. 
b. Fibrobronchoscope Olympus, model BF-TE2 working channel of 2.8mm, flexible tube of 
4.9 mm in diameter. 
During FBC, the physician evaluated the percentage of luminal obstruction of the air way 
(table 2), repeating these evaluations after the following FBC. 
At the first FBC, the extension of the lesion was measured: the anatomic potion of thee 
carina was used as reference point to measure lesion extension towards cranium or caudal. 
After confirmation of the precise target location that was recognized as clearly limited or 
demarcated, one or two endobronchial brachytherapy applicator catheters (Varian (metal-
tipped 4.7, FR-150 cm long (PTFE) R)) were installed ,, with a radiopaque terminal that 
keeps its position by means of nasal fixing. After insertion of the catheter, or in advance, we 
used of codeine for managing cough caused by the dwelling catheters in the airway.  
The HDR-EBBT planning was simulated on computer associated tomography (CAT) 
images. using planning computer ( Brachyvision system , Varian Medical Systems), which 
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was transferred to are mote high loading dose (iridium-192 source) brachytherapy 
equipment (VariSource iX, Varian Medical Systems). We prescribed 1 to 4 fractions of 7 to 
7.5 Gy (range of total, 7 – 30Gy )at 1 cm depth point from the endobronchial surface- 
covering the macroscopic lesion with a safety margin of additional 1 cm (Figure 2). The 
fractional interval between brachytherapy session was 1 week. In patients with significant or 
complete bronchial obstruction, we applied electrofulguration before installing the catheter, 
or installed the catheter through the tumor stenosis/obstruction into the peripheral end. 
Both the catheter installation procedure by BFC and HDR-EBBT were performed in an 
outpatient setting. Patients were followed up and evaluated for effect and complications at 
next week of the last brachytherapy session and at the second month. . 
 
 
Grade Description 
Dyspnea   
0 Without dyspnea 
1 Dyspnea in moderate effort 
2 Dyspnea in normal activity 
3 Dyspnea in rest 
4 Requires oxygen 
Cough   
0 Without cough 
1 Intermittent, no medication required 
2 Intermittent, no narcotics required 
3 Constant, narcotics required 
4 Constant, not improved with narcotics  
Hemoptysis   
0 Without hemoptisis 
1 Less than twice a week 
2 More than twice a week, but less an everyday 
3 Daily, red bright blood or clot 
4 Hemoglobin decreases and/or hematocrit in more than 10% or more 
than 150 ml. Requires to be admitted in hospital or transfusion of more 
than 2 U of red blood cells.  
 
Table 1. Sympton's scale of American Brachytherapy Society (Speiser and Spratling) 
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Grades Obstruction 
G0 Without evidences of obstruction 
G1 Equivalent or less than 25% of obstruction 
G2 Obstruction between 25-75% 
G3 Obstruction more than 75% 
G4 Full obstruction 
Table 2. Grade of obstruction 
3. Results 
Patient consisted of 15 men and 12 women and their age ranged 32-85 years old. The most 
frequent histologic cancer type was NSCLC, with the main subtype being squamous 
carcinoma (40%). 7 patients (26%) were previously treated with palliative radiotherapy:(5 
patients received 40 Gy in 20 fractions, one received 30 Gy in 10 fractions, one 20 Gy in 5 
fractions and the other one 8 Gy in 1 fraction.. At the time of EBBT no patients were 
receiving concomitant chemotherapy, while a few received chemotherapy previously for 
relapsed tumor. Table 3 summarizes the characteristics of the 27 patients who received 
HDR-EBBT. 
Lesion location, extent and degree of airway obstruction are described in Table 3 and Figure 3. 
With this treatment, a significant improvement was observed in every evaluated symptom 
(hemoptysis, cough, dyspnea and obstruction). Table 4 compares symptomatic scores before 
and 1 week after treatment. One patient did not complete treatment for personal reasons, 
and another one died secondary to a hemorragic complication from the contralateral 
bronchial tree. Thus 25 patients were evaluable for dyspnea, hemoptysis and cough. 22 
patients underwent bronchoscopic reevaluation for degree of obstruction after treatment: 
One patient with significant clinical improvement refused the reevaluation. 
 
Fig. 2. Dose distribution of a treatment planning to main left bronchus lesion causing left 
superior lobar atelectasis. Thick green line: catheter in treatment position: Cayn clouered 
contur between red and yellow indicates 100% of the prescribed dose . 
www.intechopen.com
High Dose Rate Endobronchial Brachytherapy  
in Lung Cancer in Patients with Central Airway Obstruction 
 
83 
Variables Number (%) 
Age (years)   
Mean ± standard deviation 63,07 ± 12,95 
Sex  
Male 15 (56%) 
Female 12 (47%) 
Diagnosis  
Lung Cancer 21(78%) 
Amyloidosis  1 (3%) 
Esophageal Cancer  1 (3%) 
Renal cancer  3 (12%) 
Bronchial carcinoid  1 (3%) 
Cancer Histology  
Adenocarcinoma 10 (37%) 
Epidermoid 11 (40%) 
Undifferentiated NSCLC  1 (3%) 
Bronchial carcinoid  1 (3%) 
CP large cell  1 (3%) 
Small cell CP  1 (3%) 
Cancer Stages  
IIIA  1 (4%) 
IIIB  7 (28%) 
IV 16 (64%) 
Relapses  1 (4%) 
Location  
Right bronchus 18 (66%) 
Left bronchus 11 (40%) 
Carina 14 (51%) 
Trachea  4 (14%) 
Palliative external beam radiotherapy (overprint)   8 (30%)  
Total number of staged patinets is 26 because eliminating a patients with benign concurrent disease. 
Most of the patients had more than one location.  
Table 3. This table summarizes the characteristics of the 27 patients who underwent 
endobronchial brachytherapy high doses (HDR-EBBT) 
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Variable Degree of 
symptoms 
Prior to the EBBT n 
patients (%) 
Post to the EBBT    n° 
patients (%) 
Dyspnea G0 3 (11,1%) 10 (37%) 
G1 2 (7,4%) 13 (48,1%) 
G2 13 (48,1%) 2  (7,4%) 
G3 8 (29,6%) 0 
G4 1 (3,7%) 0 
Hemoptysis G0 4 (14,8%) 25 (92,6%) 
G1 3 (11,1) 0 
G2 9 (33,3%) 0 
G3 11 (40,1%) 0 
G4 0 0 
Obstruction G0 1 (3,7%) 9  (33,3%) 
G1 4 (14,8%) 12 (44,4%) 
G2 11 (40,07%) 1  (3,7%) 
G3 8 (29,6%) 0 
G4 3 (11,1%) 0 
Cough G0 3 (11,1%) 9  (33,3%) 
G1 2 (7,4%) 13 (48,1%) 
G2 9 (33,3%) 3  (11,1%) 
G3 13 (48,1%) 0 
G4 0 0 
Table 4. Patient symptoms according to the Speiser-Spratling scale before and after HDR-
EBBT 
Symptomatic improvement was observed in all hemoptysis condition, 40% of dyspnea, and 
25% coughing condition after treatment. After treatment, no patient had G3 or G4 
symptoms. 
The EBBT procedure was well tolerated, with no acute complications registered. Two 
months after treatment, two patients (7%) had significant hemoptysis and bronchoscopic 
examination revealed these bleeding were originated from different locations.. One patient 
discontinued treatment because of personal choice. 
The average treated volume (100% isodose) was 38.1 cm3(SD  15.4)(this shows the 
smallness of the irradiated tissue volume with this technique) 
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4. Discussion 
The HDR-EBBT provides rapid and significant symptomatic improvement of related to 
main airway obstruction when the selection of patients is adequate. Our results are 
consistent with that reported previously (Table 5). These excellent results, with the progress 
in radioisotope security issue and the outpatient treatment possibility owing to recent 
decade’s technological advances, have made EBBT one of the major applications of 
brachytherapy in several nations16.  
Currently, EBBT is a part of the therapeutic arsenal in interventional bronchoscopy, being 
complementary to other techniques such as cryotherapy, laser, photodynamic, stents and 
argon plasma17. 
EBBT Indications  
There are several comprehensive publications that develop the indications and treatments 
techniques6, 18.19. 
According to the recommendations of the ABS (American Brachytherapy Society)18 and the 
ESTRO (European Society of Therapeutic Radiology and Oncology)19 indications could be 
divided into: Palliative treatment, healing and non-oncologic pathology. 
1. Palliative treatment 
Patients with large endobronchial tumors which cause symptoms such as dyspnea due to 
obstruction, cough, bleeding, or post obstructive pneumonia, represent the most common 
EBBT indication. Contrary, those tumors that cause obstruction mainly due to extrinsic 
airway compression would not be candidates for this treatment. Patients with critical 
obstruction and airway compromise are not recommended for exclusive use of this 
technique, but it can be used after initial treatment with laser, cryotherapy, stents or 
electrocautery20, 21 with great results and ostensible improvement in quality of life. 
According to Nag18, the EBBT might be more effective than a two or three weeks treatment 
with external beam radiotherapy (EBRT), indicated at first instance, in patients with life 
expectancy greater than three months that are not candidates for surgery or EBRT due to 
poor lung function after radiation therapy. Kelly et al, from MD Anderson, discussed their 
10 years’ experience with EBBT11. These authors treated a group of patients with the worst 
prognosis. Given that, two thirds had already received palliative EBRT. However, they got a 
66% improvement of symptoms. Escobar-Sacristán et al, from the Military Hospital of 
Madrid, reported 85 patients with symptomatic advanced lung cancer who received 288 
EBBT applications with 85% partial improvement in symptoms (cough, dyspnea, 
hemoptysis, and obstruction) and 60% complete responses using endoscopic EBBT22. 
The treatment schedule, i.e., the dose and the number of applications vary in different sites 
and authors as shown in Table 5. When treatment is performed exclusively, most 
publications have suggested dose and fractionation schemes between 15 and 35 Gy in one to 
five applications, calculated within 1 cm from the source. However, more recent studies 
recommended not exceeding 30 Gy with EBBT19. The ABS recommends 3 fractions of 7.5 Gy, 
two of 10 Gy or four of 6 Gy. These fractions have the same radiobiological equivalent 
according to the linear quadratic model23, and the results are very similar,7,13,24-26. 
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Authors Nº  
of patients 
Dose and 
fraction 
Results 
Macha et al9 365 5 Gy/3-4f 66% obstructive symptoms improvement 
Muto et al10 320 GROUP A 10 
Gy/1f 
GROUP B 7 
Gy/2f 
GROUP C 5 
Gy/3f 
94% hemoptysis and 90% dyspnea 
reduction, 70% performance status 
improvement 
Kelly et al11 175 15 gy/1f 66% symptoms and 85% endoscopic 
lesions improvement 
Petra et al12 67 5-7 Gy/1-2f 90% symptoms and 85% endoscopic 
lesion reduction  
Celebioglu et al13 95 7-10 Gy/1-3f Significant reduction of symptoms, 
hemoptysis, dyspnea and cough 
Delclos et al14 81 15 Gy/1f 62% symptomatic improvement 
Anacak et al15 28 7 Gy/3f 43% in cough, 80% in dyspnea and 95% 
in hemoptysis Improvements 
Speicer and 
Spratling8 
151 7 Gy/2-3f 99% of hemoptysis, 86% of dyspnea and 
85% of cough improvements 
Table 5. Published results of HDR endobronchial brachytherapy as palliative treatment 
2. Curative treatment 
EBBT has been used in curative treatment of lung cancer, both in the exclusive treatment of 
early tumors with EBRT as overprint (boost or reirradiation)2, 3. About the first indication, 
Marsiglia et al, reported a two year survival rate of 78% in 34 patients with small tumors 
without evidence of spread that were treated only with HDR-EBBT with a 30 Gy dose in 6 
fractions3.Hennequin et al, in a series of 106 patients with localized tumors that were not 
candidates for surgery or EBRT, obtained a specific 3 and 5 years survival of 60% and 50% 
respectively2.The ABS recommended a healing (palliative) dose is 3 fractions of 5 to 7.5 Gy 
(total 15 – 22.5Gy) when the patient already received 60 Gy pretreatment with EBRT, and 5 
to 6 fractions of 5 to 7 Gy (total 25 – 42 Gy) if this treatment is exclusively used 17. 
3. Non-oncologic pathology treatment 
Several authors have published interesting experiences regarding the use of EBBT in non-
malignant pathology. This treatment modality has been used successfully in patients with 
granulomatous proliferation after metal stent placement because of non-malignant airway 
stenosis, or pulmonary transplant patients4,5. 
In patients who have not received EBRT it is feasible to use the combination of EBBT and 
EBRT in order to improve results. In a randomized study, the combination of those 
treatments proved to be more effective than single-EBRT in symptomatic improvement27. 
Mantz and colleagues, obtained a significant increase in local control when using a EBBT 
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boost or overlay to EBRT compared to exclusively use of EBRT (58 versus 32% at 5 years, 
respectively)28. 
We understand that the EBRT is preferred as a palliative treatment when the airway 
compression is extrinsic, when EBBT is not indicated. In patients with tumors, with an 
intrinsic component in the airway lumen, Kelly and colleagues from MD Anderson, say that 
one of the advantages of HDR-EBBT would be the shorter treatment time11. 
5. Conclusion 
The HDR-EBBT is a useful technique in the symptomatic treatment of ambulatory patients 
with central airway obstruction. The procedure is well tolerated and effective with low 
complications rate. Main indications are patients with advanced lung cancer, where the 
objective is only palliative. It must also be considered in situations of incipient tumors for 
patients with contraindications for surgery or EBRT, boosted after a first treatment with 
EBRT or in benign disease with endobronchial or endotracheal scar proliferation. 
6. References 
[1] Yankauer S. Two cases of lung tumour treated bronchoscopically. NY Med J 
1922;115:741-742 
[2] Hennequin C, Bleichiner O, Trédaniel J y col. Long term results of endobronchial 
brachhytherapy: a Curative treatment? Int J radiat Oncol Biol Phys 2007;67(2);425-30. 
[3] Marsiglia H, Baldeyrou P, Larigau E, Brioth E, Haie C, Le chevalier L y col. High Dose 
Rate Brachytherapy as sole Modality for early stage Endobronchial carcinoma. In J 
Radiat Oncol Biol Phys 2000:47(3):665-672 
[4] Kramer MR, Kats A, Yarmolowsky A y col. Successful use of high dose rate 
brachytherapy for non-malignant bronchial obstruction. Thorax 2001;56:415-416 
[5] Brenner, M. R. Kramer, A. Katz, R. Feinmesser, y col. High Dose Rate Brachytherapy for 
Nonmalignant Airway Obstruction: New Treatment Option. Chest, 2003; 124(4): 
1605 - 1610. 
[6] Vergnon JM, Huber RM and Moghissi K. Place of cryotherapy, brachytherapy and 
photodynamic therapy in therapeutic bronchoscopy of lung cancers. Eur Eespir J 
2006;28;200-18 
[7] Cavaliere S, Ventura F, Foccoli P y col. Endoscopic treatment of malignant airway 
obstruction in 2008 patient CHEST 1996:110.1536-42 
[8] Speiser BL, Sparting L. Remote afterloading brachytherapy for local control of 
endobronchyal carcinoma. Int J Radiat Oncol Biol Phys 1993;25:579-87 
[9] Macha HN, Wahlers B, Reichle C y col. Endobronchial radiation therapy for obstructing 
malignancies. Ten years experience with IR192 hiagh-Dose-radiation Brach therapy 
afteroading technique in 365 patients. Lung 1999;173:274-80 
[10] Muto P, Ravo V, Pannelli C y col. High-Dose-rate brachytherapy of bronchial cancer: 
treatment optimization using thee schemes of therapy. The Oncology 2000;5:209-14 
[11] Kelly J, Delclos M, Morice R Y col. High-Dose.rate Endobroncial Brachytherapy 
afterloading palliative symptoms due to airway tumor. The ten years MD 
Anderson Cancer Center experience Int J Radiat Oncol Biol Phys 2000;48(3):697-702 
www.intechopen.com
 
Brachytherapy 
 
88
[12] Petera J, Spasora I, Neumanova R y col. High-Dose-Rate Intraluminal brachytherapy in 
treatment of malignant airway obstruction. Neoplasma 2001;48:148-153 
[13] Celebioglu B, Ural Gurkan O, Erdogan S y col. High dose rate endobronchyal 
brachytherapy effectively palliates symptoms due to inoperable lung cancer. Jpn J 
Clin Oncol 2002.32(11);443-48 
[14] Delclos ME, Komaki R, Morice RC y col. Endobronchyial brachytherapy with High-
Dose-Rate Remote afterloading for recurrent endobroncyal leson. Radiology 
1996:201:279-282 
[15] Anacak Y, Mogulkoc N, Ozkok S y col. High dose rate endobronchial brachitherapy in 
combination with external beamradiotherapy for stage III non-smal cel lung cáncer. 
Lung cancer 2001.34:253-259 
[16] The Royal College of Radiologist. The Role and development of brachitherapy service 
in United Kingdom. London : the Royal College of Radiologyst, 2007 
[17] Janssen JP, Noppen M and Rabe KF. Place of cryotherapy, brachytherapy and 
photodynamic therapy in therapeutic bronchoscopy of lung cancer. Eur Respir J 
2006;28:200-18 
[18] Nag A. Brachytherapy for carcinoma of the lung. Oncology 2001;15(3): 371-81 
[19] Van Limbergen E and Pötter R. Bonchus cancer in: Gerbaulet A, Potter R, Van 
Limbergen E, Mazeron JJ and Meertens H: GEC – ESTRO handboock of 
brachytherapy. ACCO, Belgium 2002 
[20] Freitag L, Emst E, Thomas M y col. Sequential Photodinamic therapy and HDR 
brachytherapy for endobronchial tumor control in patients with limited 
bronchogenic carcinoma. Thorax 2004;59:790-93 
[21] Wang Jan T, Blackman G, George J. Survival benefits of lung cancer patients 
undergoing Laser an Brachytherapy . J Korean Med Sci 2002;17:341-7 
[22] Escobar-Sacristán JA, Granada-Orive J, Gutierrrez T y col. Endobronchial 
brachytherapy in the treatment of maingant lung tumors. Eur resp J 2004;24;348-52 
[23] Mehta M, Petereit D, Ghosy L y col. Sequential comparison of low-dose rate and 
hyperfractioned high-dose rate endobronchyal radiation for malignant airway 
occlutions. Int J Radiat Oncol Biol Phys 192;23(1):133-39 
[24] Mallick I, Sharma S and Behera D. Endobronchyal brachytherapy for symptom 
palliation in non-small cell lung cancer – Analysis of symptom response, 
endoscopic improvement and quality of life. Lun Cancer 2007:55:313-318 
[25] Bedwinek J, Petty A, Burton C y col. The use of higth dose rate endobronchyal 
brachytherapy to palliate symptomatic endobronchyal recurrence of previously 
irradiated bronchogenic carcinoma. Int J Radiat Oncol Biol Phys 1992;22:23-30 
[26] Lu JJ, Bains Y, Aaron B y col. High dose rate endobronchial brachytherapy for the 
managent of non-small cell lung cancer with an endobronchial or peribronchial 
component. Cancer Therapy 2004.2:469-74 
[27] Huber RM, Fischer R, Hautman H Y col. Does additional brachytherapy improve the 
effect of external irradiation? A prospective randomized study in central lung 
tumors Int J radiat Oncol Biol Phys 1997;38:53-540 
[28] Mantz C, Dosoretz E, Rubeistein H y col. Endobronchial brachytherapy and 
optimization of local disease control in medically inoperble non-small cell lung 
carcinoma: A matched-pair analysis. Brachyterapy 2004;83;183.190 
www.intechopen.com
Brachytherapy
Edited by Dr. Kazushi Kishi
ISBN 978-953-51-0602-9
Hard cover, 128 pages
Publisher InTech
Published online 25, April, 2012
Published in print edition April, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
Importance of brachytherapy is currently increasing in cancer therapy. In brachytherapy each treatment is best
fitted by physician's' hand, and appropriate arrangement and selection of radiation sources facilitates the
fitting. This book is full of essences to make a breakthrough in radiation oncology by brachytherapy. I hope this
book will encourage all people related. Contents 1: problem of currently popular dosimetric method; 2: Monte
Carlo dose simulation of ruthenim-106/rhodium-106 eyes applicators; 3. Progress in Californium-252 neutron
brachytherapy; 4. Clinical aspect of endobronchial brachytherapy in central airway tumor obstruction; 5.
Review from principle and techniques of Iodine-125 production at nuclear reactor plant to their clinical practive
in prostate cancer treatment; 6. Stereotactic Brachytherapy for Brain Tumors using Iodine-125 seed; 7. A
brachytherapy procedure with organ-sparing hyaluronate gel injection for safe and eradicative reirradiation.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Alejandro B. Santini, Benjamín G. Bianchi, Dionis D. Isamitt, Claudia C. Carvajal and Gonzalo P. Silva (2012).
High Dose Rate Endobronchial Brachytherapy in Lung Cancer in Patients with Central Airway Obstruction,
Brachytherapy, Dr. Kazushi Kishi (Ed.), ISBN: 978-953-51-0602-9, InTech, Available from:
http://www.intechopen.com/books/brachytherapy/the-role-of-brachytherapy-in-the-management-of-advanced-
lung-cancer
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
